Current Status of Cardiovascular Tissue Engineering

Abstract

The development of vascular and heart valve surgeries have contributed to improve outcomes in patients with cardiovascular disease. However, there are drawbacks, such as risk of infection and lack of growth potential. Tissue engineered vascular graft (TEVG) and tissue engineered heart valve (TEHV) hold great promise to address these drawbacks as the ideal TEVG and TEHV is easily implanted, biocompatible, non thrombogenic, durable, degradable, and ultimately remodels into nativelike tissue. In general, the TEVG and/or TEHV concept consists of scaffold, cells for scaffold seeding, and a subsequent remodeling process driven by cell accumulation and proliferation, and/or biochemical and mechanical signaling. Despite rapid progress in the field over the past decade, small-diameter arterial TEVG and TEHV have not been translated into clinical applications successfully. To successfully utilize TEVGs and TEHVs clinically, further elucidation of the mechanisms for TEVG and TEHV remodeling and further translational research outcome evaluations will be required.

Authors and Affiliations

Toshiharu Shinoka

Keywords

Related Articles

Endometrial Cancer - Diagnosis

Endometrial Cancer - Diagnosis

Vitamin D Deficiency in a Sunny Country: The Missing Chain

Vitamin D deficiency continues to be an important health problem around the world. It has been reported in healthy children, young adults, middle age adults and elderly, and common among both males and females. Recent st...

Primary Adrenal Insufficiency (PAI): A Major Teaching Hospital Experience, Riyadh, Saudi Arabia

Background: Primary adrenal insufficiency (PAI) in children is an uncommon, but potentially fatal. The current symptoms include weakness, fatigue, anorexia, abdominal pain, weight loss, orthostatic hypotension, salt crav...

Medico-Legal Evaluation of Sudden Cardiac Deaths in Albania, 2014-2015

Sudden cardiac death is an occurrence of extreme severity, with medical, legal, social and public health implications. We have studied the forensic registers with regard to sudden deaths due to heart disease during the y...

ErbB Targeted Therapy in Endometrial Cancer

The potential role of ErbB receptors (especially EGFR and ErbB-2) as targets for cancer therapy has been investigated for over 30 years. Anti-ErbB monoclonal antibodies (MoAbs) bind to the extracellular domain of EGFR or...

Download PDF file
  • EP ID EP202987
  • DOI 10.19070/2332-2926-SI03001
  • Views 135
  • Downloads 0

How To Cite

Toshiharu Shinoka (2015). Current Status of Cardiovascular Tissue Engineering. International Journal of Clinical Therapeutics and Diagnosis (IJCTD), 0(1), 1-10. https://europub.co.uk/articles/-A-202987